<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>4(11)</volume><submitter>Jin YJ</submitter><pubmed_abstract>&lt;h4>Objective&lt;/h4>To evaluate clinicobiochemical factors predicting severe hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection.&lt;h4>Setting&lt;/h4>Tertiary institution.&lt;h4>Participants&lt;/h4>859 treatment-naïve Korean patients with HCV who underwent liver biopsy. Severe fibrosis was defined as fibrosis stage ≥3 based on the METAVIR system.&lt;h4>Primary outcome measures&lt;/h4>Clinicobiochemical factors predicting severe hepatic fibrosis.&lt;h4>Results&lt;/h4>The median serum alanine aminotransferase (ALT) level was 68 IU/L and body mass index (BMI) was 24.2 kg/m(2). Severe fibrosis was observed in 326 (39.7%) of the 859 patients. The frequencies of severe fibrosis were 0%, 37.8%, 41.9% and 42% in patients with serum ALT concentrations (IU/L) of ≤20, 20-30, 30-40 and >40 (p&lt;0.01), re</pubmed_abstract><journal>BMJ open</journal><pagination>e006255</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4248083</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection.</pubmed_title><pmcid>PMC4248083</pmcid><pubmed_authors>Lim YS</pubmed_authors><pubmed_authors>Jin YJ</pubmed_authors><pubmed_authors>Lee HC</pubmed_authors><pubmed_authors>Shim JH</pubmed_authors><pubmed_authors>Kim KM</pubmed_authors><pubmed_authors>Yu E</pubmed_authors><pubmed_authors>Kim GA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection.</name><description>&lt;h4>Objective&lt;/h4>To evaluate clinicobiochemical factors predicting severe hepatic fibrosis in patients with chronic hepatitis C virus (HCV) infection.&lt;h4>Setting&lt;/h4>Tertiary institution.&lt;h4>Participants&lt;/h4>859 treatment-naïve Korean patients with HCV who underwent liver biopsy. Severe fibrosis was defined as fibrosis stage ≥3 based on the METAVIR system.&lt;h4>Primary outcome measures&lt;/h4>Clinicobiochemical factors predicting severe hepatic fibrosis.&lt;h4>Results&lt;/h4>The median serum alanine aminotransferase (ALT) level was 68 IU/L and body mass index (BMI) was 24.2 kg/m(2). Severe fibrosis was observed in 326 (39.7%) of the 859 patients. The frequencies of severe fibrosis were 0%, 37.8%, 41.9% and 42% in patients with serum ALT concentrations (IU/L) of ≤20, 20-30, 30-40 and >40 (p&lt;0.01), re</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014 Nov</publication><modification>2025-04-19T23:10:55.137Z</modification><creation>2019-03-27T01:40:30Z</creation></dates><accession>S-EPMC4248083</accession><cross_references><pubmed>25431223</pubmed><doi>10.1136/bmjopen-2014-006255</doi></cross_references></HashMap>